



Kepler Cheuvreux Digital Life Science Day
22 June 2021

Forward-Looking Statements

This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, "presentation" means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person's organization or firm) or published for any purpose or under any circumstances.


This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company.

15,000 drugs in
development in
2018



60 hit
the
market
in 2018

High Unmet Medical Needs



Rethinking, Reinventing, Optimising Existing Medications

To improve overall therapy outcomes

REFORMULATING



Changing dose or mode of administration

REPURPOSING



Finding new indications

For the benefit of patients, physicians, payors

Hyloris: Potential Game Changer

Growth Pillars

11 patented product candidates in the pipeline

Spread across stages and indications

Expand with 4 products on average per year

MULTIPLE SHOTS ON GOAL

2 products on the market with partners

Build own, lean, U.S. commercial team

14 approved products by 2024 anticipated

COMMERCIAL PORTFOLIO

Patients, partners, physicians and KOLs


Real-world data and payors' input

Outsourcing of non-core activities

VALUED PARTNERS

Patented Value-Added Medicines: Pharma's Sweet Spot

To improve therapy outcomes



Faster Innovation at Much Lower Costs and Risks




Putting Healthcare Needs at the Centre of Therapy Design

UNMET
MEDICAL
NEEDS



To Drive Continuous Growth and Create Shareholders' Value



Broad, Innovative Portfolio: Expand to ~30 Assets by 2024

Product	RoA	Indication	Formulation and Manufacturing	Clinical Development	Regulatory Filing	Expected Launch
CARDIOVASCULAR (CV) PORTFOLIO			Maximum 7 years on average			
Sotalol IV	IV	Atrial fibrillation	<i>Launched in U.S./partnered with AltaThera</i>			🇺🇸 '20 ¹ ✓
Dofetilide IV	IV	Atrial fibrillation	████████████████████			🇺🇸 '23
Metolazone IV	IV	Congestive heart failure	██████████████████			🇺🇸 '24
HY-073	IV	Coronary heart disease	██████████████████			🇺🇸 '25
HY-074	IV	Coronary heart disease	██████████████████			🌐 '25
HY-075	Oral Liquid	Coronary heart disease	██████████████████			🇺🇸 '24
OTHER VALUE-ADDED PORTFOLIO			Maximum 7 years on average			
Maxigesic® IV	IV	Post-operative pain	<i>Licensed in >100 countries/partnered with AFT Pharmaceuticals</i>			🌐 '20 ² ✓
TXA Acid RTU	IV	Excessive bleeding	██			🌐 '22
HY-038	IM	(Specific) deficiency	██			🇺🇸 '23
HY-004	Oral Liquid	Specific dental indication	██			🌐 '24
Miconazole-DB	Topical	Severe and rVVC	██			🌐 TBD
Atomoxetine	Oral Liquid	ADHD	██			🇺🇸 '23
HY-029	Oral Liquid	Viral infection	████████████████████			🇺🇸 '24


¹ Under the new expanded label

² Marketing application to the U.S. FDA currently being prepared


Our two high barrier generic products, HY-016 and Fusidic Acid not included

█ Intended to be commercialised by Hyloris
█ Intended to be commercialised with partner

Sourcing Product Opportunities Via Multiple Channels



Powerful R&D Engine: Leveraging our Network of Partners



2020 has Set Strong Foundations for Value-Creation

R&D - Regulatory

- Sotalol IV: U.S. approval expanded label
- Maxigesic IV: approvals in 17 EU countries; Phase 3 completed
- Further advanced all other pipeline assets

Commercial

Maxigesic IV:

- Licensed in >100 countries
- Launched in 3 countries

Corporate

- Raised €79.54M
- Strengthened management team
- Further built internal resources
- Reinforced Board of Directors


Share Price since IPO June 2020

Absolute performance Since IPO



Market cap (June '21): €350 million

Relative performance Since IPO



Euronext

Core Assets: Anticipated Value Inflection Milestones in 2021

Clinical



HY-004: start Phase 1

- Atomoxetine: start + results pivotal study
- Dofetilide IV: start pivotal study
- HY-004: results Phase 1 and preparations pivotal study
- Miconazole-DB: start Phase 2 study
- Other assets: preparations to start pivotal studies

Regulatory



Tranexamic Acid RTU: marketing application in U.S.

- Maxigesic IV: marketing application in U.S.
- Maxigesic IV: additional approvals in key markets

Commercial



Partnership Purna Female Healthcare



Maxigesic IV: distribution agreements in EU and S. America



Maxigesic IV: agreement with Hikma in the U.S.



Maxigesic IV further roll-out

- Commercial partnership(s)
- In-licensing and out-licensing agreement(s)
- Sotalol IV U.S. roll-out

Hyloris: Potential Game Changer, Geared for Growth

MULTIPLE SHOTS ON GOAL

≤ 7 Years to Market

≤ €7 million Cost to Market

Lower risk as we start from existing drugs

Innovative, patented, value-added drug candidates

COMMERCIAL PORTFOLIO

2 patented products with partners

Addressing unmet needs

Build **U.S. commercial** team

14 approved products **by 2024** anticipated

Ambition to become the reference in value-added medicines over the coming years



investorrelations@hyloris.com

